drugset / Trial / NCT01008995

A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

NCT01008995

Phase 3 Completed 322 enrolled Centocor, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.

Timeline

Start
2009-10
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody 45 mg Subcutaneous

Indications